Lifesci Capital Downgrades Mersana Therapeutics (NASDAQ:MRSN) to Hold
I'm PortAI, I can summarize articles.
Lifesci Capital downgraded Mersana Therapeutics (NASDAQ:MRSN) from a "strong-buy" to a "hold" rating. Other analysts, including Guggenheim, BTIG Research, Truist Financial, Wedbush, and William Blair, also downgraded the stock. The stock has an average rating of "Reduce" and a price target of $38.19. Mersana's shares rose to $27.92, with a market cap of $139.35 million. The company reported a quarterly loss, missing estimates. Institutional investors hold 93.92% of the stock. Mersana develops ADCs for cancer treatment and collaborates with several biotech firms.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments